AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pharmaceutical Companies

806.248

-3.677-0.45%

Number of Gainers:9

Number of Losers:14

Number of Flat:22

PE:- -

High:816.991

Open:809.925

Low:806.079

Close:809.925

Loading ...

These are the 10 most shorted ASX shares

BRIEF-Oncosil Medical Says A$8.7M Capital Raise At Issue Price A$0.003 Per Share

Immutep Combination Therapy Increases Tumor Fibrosis Rate in Soft Tissue Sarcoma Trial

MT Newswires Live

Immutep Ltd. Secures Polish Government Grant for EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

Oncosil Medical Ltd-Proposed Issue of Securities - OSL

THOMSON REUTERS

Oncosil Medical Ltd - a$8.7M Capital Raise at an Issue Price of a$0.003 per New Share

THOMSON REUTERS

Want to beat the stock market? I'd focus on buying these ASX shares

These ASX 200 shares could rise 20% to 100%

Buy these fantastic ASX shares for your SMSF

How $500 a month in ASX shares could make you wealthy

CSL Ltd - England's Nice Recommends Filspari as a Treatment Option for Iga Nephropathy

THOMSON REUTERS

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

Neuren Pharmaceuticals Grants Share Options After FDA Meeting

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK7508/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":806.24774,"timestamp":1749189599976,"preClose":809.925,"halted":0,"volume":49882817,"delay":0,"changeRate":-0.00454,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-3.677246,"latestTime":"06-06 16:00:00 AEST","open":809.925,"high":816.99097,"low":806.07916,"amount":127636809,"amplitude":0.013473,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1749513600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1749168000000,1749189600000]],"turnoverRate":0.001585,"increases":8,"decrements":16,"flats":19,"marketCap":126924971440.99219,"floatMarketCap":124496830075.07617},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":816.99097,"amplitude":0.013473,"preClose":809.925,"low":806.07916,"latestPrice":806.24774,"volume":49882817,"delay":0,"open":809.925,"prevYearClose":936.801,"prevWeekClose":825.374,"prevMonthClose":825.374,"prevQuarterClose":815.605,"fiveDayClose":825.374,"twentyDayClose":797.289,"sixtyDayClose":829.898,"secType":"PLATE","market":"AU","turnoverRate":0.001585,"marketCap":126924971440.99219,"floatMarketCap":124496830075.07617,"timestamp":1749189599976,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":9,"down":14,"flat":22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538714057","title":"These are the 10 most shorted ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2538714057","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538714057?lang=en_us&edition=fundamental","pubTime":"2025-05-26 09:50","pubTimestamp":1748224200,"startTime":"0","endTime":"0","summary":"At the start of each week, I like to look atASIC's short position reportto find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/26/these-are-the-10-most-shorted-asx-shares-26-may-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CTT.AU","IEL.AU","BOE.AU","BK7507","PDN.AU","BK7095","BK7126","PLS.AU","DYL.AU","LTR.AU","BK7504","BK7083","PNV.AU","MIN.AU","BK7132","BK7021","BK7509","BK7508","KAR.AU","BK7142","BK7049"],"gpt_icon":0},{"id":"2538178142","title":"BRIEF-Oncosil Medical Says A$8.7M Capital Raise At Issue Price A$0.003 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2538178142","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538178142?lang=en_us&edition=fundamental","pubTime":"2025-05-26 09:31","pubTimestamp":1748223095,"startTime":"0","endTime":"0","summary":"BRIEF-Oncosil Medical Says A$8.7M Capital Raise At Issue Price A$0.003 Per ShareMay 26 (Reuters) - Oncosil Medical Ltd OSL.AX:A$8.7M CAPITAL RAISE AT AN ISSUE PRICE OF A$0.003 PER NEW SHAREFurther company coverage: OSL.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nFWN3RX03A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7048","OSL.AU"],"gpt_icon":0},{"id":"2538314447","title":"Immutep Combination Therapy Increases Tumor Fibrosis Rate in Soft Tissue Sarcoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2538314447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538314447?lang=en_us&edition=fundamental","pubTime":"2025-05-26 09:06","pubTimestamp":1748221581,"startTime":"0","endTime":"0","summary":"Immutep  said its Phase II EFTISARC-NEO trial evaluating the therapy of the company's drug candidate eftilagimod alfa, in combination with prescription medicine Keytruda and radiotherapy as treatment for patients with resectable soft tissue sarcoma , showed an increase in tumor fibrosis rate, according to a Monday filing with the Australian bourse.The trial showed that the combination therapy exceeded the median tumor fibrosis rate of 35% compared to the historical median of 15% observed with radiotherapy alone, meeting the trial's primary endpoint, the filing said.Tumor fibrosis is linked to improved overall and recurrence-free survival in patients with STS.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2538444131","title":"Immutep Ltd. Secures Polish Government Grant for EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2538444131","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538444131?lang=en_us&edition=fundamental","pubTime":"2025-05-26 09:05","pubTimestamp":1748221552,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on May 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nNDL5vlndY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"2538714750","title":"Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2538714750","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538714750?lang=en_us&edition=fundamental","pubTime":"2025-05-26 08:43","pubTimestamp":1748220200,"startTime":"0","endTime":"0","summary":"Commenting on the clinical trial results helping boost the ASX 300 healthcare stock today, medical oncologists Katarzyna Kozak and Pawe Sobczuk at MSCNRIO, said:  It is very encouraging to see the chemotherapy-free combination with efti far exceed the ambitious target we initially set for the trial's primary endpoint in resectable soft tissue sarcoma. These results support our belief that efti's activation of antigen-presenting cells, and in turn a broad adaptive and innate immune response, helps transform the immunosuppressed tumour microenvironment of soft tissue sarcomas leading to strong anti-cancer efficacy.  The oncologists added, \"There remains a very high unmet need in this aggressive orphan cancer indication, and we look forward to presenting detailed results at a medical meeting later this year.\" Immutep share price snapshot Despite the big lift since April's one-year lows, with today's intraday boost factored in, shares in the ASX 300 healthcare stock remain down 33% since t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/26/up-34-since-april-asx-300-healthcare-stock-lifts-off-again-today-on-new-milestone/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XKO.AU","BK7508","BK7067","IMM.AU"],"gpt_icon":0},{"id":"2538214173","title":"Oncosil Medical Ltd-Proposed Issue of Securities - OSL","url":"https://stock-news.laohu8.com/highlight/detail?id=2538214173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538214173?lang=en_us&edition=fundamental","pubTime":"2025-05-26 08:33","pubTimestamp":1748219615,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nTUE2X8RW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OSL.AU","BK7048","BK7508"],"gpt_icon":0},{"id":"2538141910","title":"Oncosil Medical Ltd - a$8.7M Capital Raise at an Issue Price of a$0.003 per New Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2538141910","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538141910?lang=en_us&edition=fundamental","pubTime":"2025-05-26 08:18","pubTimestamp":1748218737,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250526:nFWN3RX03A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","OSL.AU","BK7508"],"gpt_icon":0},{"id":"2538468531","title":"Want to beat the stock market? I'd focus on buying these ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2538468531","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538468531?lang=en_us&edition=fundamental","pubTime":"2025-05-26 05:00","pubTimestamp":1748206800,"startTime":"0","endTime":"0","summary":"The stock market can be a great way for investors to build wealth. There are some ASX shares that I think will beat the overall market. The overall ASX share market return is mostly dictated by the bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/26/want-to-beat-the-stock-market-id-focus-on-buying-these-asx-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["WTC.AU","BK7002","BK7099","BK7135","BK7107","CBA.AU","BK7503","BK7508","BK7501","BK7046","BK7511","BHP.AU","BK7016","NAB.AU","BK7155","ANZ.AU","BK7507","BK7094","BK7137","CSL.AU","BK7041","REA.AU","WES.AU","MQG.AU","GYG.AU","TPW.AU","TUA.AU","BK7153","BK7067","WBC.AU","BK7042","BK7049","GMG.AU","TLS.AU","BK7510","XRO.AU","PME.AU","BK7095"],"gpt_icon":0},{"id":"2538190898","title":"These ASX 200 shares could rise 20% to 100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2538190898","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538190898?lang=en_us&edition=fundamental","pubTime":"2025-05-25 06:01","pubTimestamp":1748124060,"startTime":"0","endTime":"0","summary":"Are you looking for some new additions to your investment portfolio that have the potential to supercharge your returns?If you answered yes to that, then read on!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/25/these-asx-200-shares-could-rise-20-to-100/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7055","BK7108","BK7067","BK7501","MSB.AU","WOR.AU","BK7508"],"gpt_icon":0},{"id":"2537716364","title":"Buy these fantastic ASX shares for your SMSF","url":"https://stock-news.laohu8.com/highlight/detail?id=2537716364","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537716364?lang=en_us&edition=fundamental","pubTime":"2025-05-24 07:07","pubTimestamp":1748041620,"startTime":"0","endTime":"0","summary":"When it comes to managing your self-managed super fund (SMSF), the goal is clear: grow your wealth, protect your capital, and generate reliable returns over the long term. That's why choosing the righ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/24/buy-these-fantastic-asx-shares-for-your-smsf/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2237443622.USD","IE0002270589.USD","LU0742534661.SGD","XRO.AU","BK7002","LU2237443549.SGD","IE0004091025.USD","BK7503","LU2471134796.USD","LU1868837136.USD","LU1791807156.HKD","BK4516","LU2237443465.HKD","BK7501","LU0096364046.USD","BK4504","BK4550","IE00BFXG1179.USD","TLX.AU","BK7067","LU1668664300.SGD","GMG.AU","BK4585","BK7510","BK7016","IE00B19Z3581.USD","BK7511","LU0048573561.USD","BK4588","LU1868836757.USD","LU2237443895.HKD","BK4127","LU2237438978.USD","LU2750360997.AUD","REA.AU","IE00BSNM7G36.USD","LU0251142724.SGD","IE0034235188.USD","BK4552","BK7508","IE0004086264.USD","IE00B19Z3B42.SGD","BK7155","LU0106831901.USD","LU0251131958.USD","LU0061475181.USD","LU2471134523.USD","LU2471134879.HKD","LU2237443978.SGD","CSL.AU"],"gpt_icon":0},{"id":"2537410159","title":"How $500 a month in ASX shares could make you wealthy","url":"https://stock-news.laohu8.com/highlight/detail?id=2537410159","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537410159?lang=en_us&edition=fundamental","pubTime":"2025-05-24 01:09","pubTimestamp":1748020140,"startTime":"0","endTime":"0","summary":"Ask most people what it takes to build wealth from the share market and you'll often hear talk of six-figure windfalls or well-timed trades. But the truth is, you don't need a huge upfront investment or perfect timing — you just need consistency, time, and a focus on quality. In fact, investing just $500 a month into high-quality ASX shares could be enough to build serious wealth over time. And history backs that up. Compounding with ASX shares Let's start with the numbers. If you invest $500 each month and earn a long-term average return of 10% per annum, your portfolio could grow to over $1 million in approximately 30 years. That 10% figure isn't pulled from thin air. It is roughly in line with the long-term historical average return of share markets, including dividends. Of course, past performance is no guarantee of future results. And it is worth remembering that the ride won't be smooth. Markets don't move in a straight line. There will be volatility. There will be corrections. B","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/24/how-500-a-month-in-asx-shares-could-make-you-wealthy/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","REA.AU","WTC.AU","CSL.AU","BK7016","BK7067","BK7511","BK7503","BK7501","BK7002"],"gpt_icon":0},{"id":"2537888841","title":"CSL Ltd -  England's Nice Recommends Filspari as a Treatment Option for Iga Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2537888841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537888841?lang=en_us&edition=fundamental","pubTime":"2025-05-23 16:00","pubTimestamp":1747987219,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nFWN3RV06E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7511","CSL.AU","BK7508"],"gpt_icon":0},{"id":"2537906573","title":"Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2537906573","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537906573?lang=en_us&edition=fundamental","pubTime":"2025-05-23 12:36","pubTimestamp":1747974977,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index(ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.15% to 8,361.9 points. Four ASX shares that are rising more ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/23/why-arb-block-mayne-pharma-and-paladin-energy-shares-are-charging-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2357305700.SGD","BK4581","IE00BZ1G4Q59.USD","BK4585","LU1720051108.HKD","LU1732799900.SGD","LU2347655156.SGD","LU0098860793.USD","BK7083","XJO.AU","IE00BKVL7J92.USD","BK4588","00495","LU2028103732.USD","LU2023251221.USD","BK4127","LU2271345857.HKD","LU0795875086.SGD","LU1668664300.SGD","LU1162221912.USD","BK7508","PDN.AU","BK1258","LU1074936037.SGD","MYX.AU","LU0158827948.USD","BK4534","LU1363072403.SGD","LU1989772840.SGD","LU0106831901.USD","XYZ.AU","BK7509","LU0106261372.USD","LU0006306889.USD","LU2089283258.USD","ARB","BK1229","LU0267386448.USD","LU2111349929.HKD","LU1720051017.SGD","LU2133065610.SGD","LU1732800096.USD","LU0795875169.SGD","BK7051","BK4504","BK4516","LU0158827781.USD","LU0971096721.USD","LU0314104364.USD","ARB.AU"],"gpt_icon":0},{"id":"2537908759","title":"Neuren Pharmaceuticals Grants Share Options After FDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2537908759","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537908759?lang=en_us&edition=fundamental","pubTime":"2025-05-23 11:37","pubTimestamp":1747971421,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  has approved the issue of new 2.16 million share options as a long-term incentive at an exercise price of AU$12.91, according to a Friday Australian bourse filing.The issue follows its meeting with the US Food and Drug Administration for Phelan-McDermid syndrome, a neurodevelopmental disorder for which it's developing its drug candidate NNZ-2591.The exercise price is equal to the volume-weighted average price of trading during the five days before the issue, and the options expire five years after the issue.Out of the total, 360,000 options for Chief Executive Officer Jon Pilcher will be subject to shareholder approval and will not be issued before receiving said approval at a future meeting.The company will vest one-third of the options upon each of the following milestones: completion of last patient dosing in a Phase 3 trial, acceptance for filing of a marketing application or completion of a major partnership deal, and first patient dosing in a pivotal trial","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":74,"code":"91000000","status":"200"}]}}